John Wiley & Sons B (WLYB)

John Wiley & Sons, Inc. is a US-listed publishing company focused on authoritative content, data-driven insights, and knowledge services for science, innovation, and learning. Its Research segment publishes scientific, technical, medical, and scholarly journals and related content across areas including physical sciences and engineering, health sciences, social sciences and humanities, and life sciences. The segment serves research libraries, library consortia, researchers, professional society members, and other customers through direct channels and subscription agents. Wiley’s Learning segment provides print and digital books, digital courseware, and assessment services for students, instructors, businesses, and professionals. Its offerings reach a range of categories, including business and leadership, technology, behavioral health, engineering and architecture, science, and professional education, through retailers, wholesalers, college bookstores, corporations, distributors, and government agencies. Founded in 1807 and headquartered in Hoboken, New Jersey, the company operates internationally across the United States, China, the United Kingdom, Japan, Australia, and other markets.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-WLYB
$63.59
26.5% Upside
Undervalued
Good
July 7, 2026
July 23, 2026
1.43
2.9%
September 3, 2026
11.5x
3.0x
1.5x
2.533 B
3.233 B
22.8%
76.1%
6.1
33.6%
94.5%
Valuation • Fair Value

John Wiley & Sons B (NYSE-WLYB) Fair Value by Valuation Model

Compare the primary fair value estimate for John Wiley & Sons B (NYSE-WLYB) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$63.59

Estimated upside of 26.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$67.76

Discounted cash flow valuation reference.

Ben Graham Formula Value

$48.44

Classic Ben Graham valuation formula reference.

DDM Fair Value

$92.03

Dividend discount model valuation reference.

EPV Fair Value

$35.31

Earnings power value estimate.

Comps Fair Value

$54.66

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for John Wiley & Sons B (NYSE-WLYB) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for John Wiley & Sons B (NYSE-WLYB)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.677 B

Current operating scale indicator.

Revenue Forecast

1.755 B

Forward revenue estimate.

EBITDA

351.8 M

Current operating profitability reference.

EBITDA Forecast

480 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review John Wiley & Sons B (NYSE-WLYB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for John Wiley & Sons B (NYSE-WLYB)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.46

No elevated caution signal from this screen.

Altman Z-Score

6.1

Relatively strong balance-sheet zone.

FCF / Net Income

94.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for John Wiley & Sons B (NYSE-WLYB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for John Wiley & Sons B (NYSE-WLYB)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 3, 2026

Days to Earnings

44

Dividend Payment Date

July 23, 2026

Ex-Dividend Date

July 7, 2026

Dividend Yield

2.9%

Income yield reference.

Upcoming Dividend

1.43

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

33.6%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for John Wiley & Sons B (NYSE-WLYB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

John Wiley & Sons B (NYSE-WLYB) Stock Forecast & Technical Outlook

Review John Wiley & Sons B (NYSE-WLYB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for John Wiley & Sons B (NYSE-WLYB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for John Wiley & Sons B (NYSE-WLYB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for John Wiley & Sons B (NYSE-WLYB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for John Wiley & Sons B (NYSE-WLYB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for John Wiley & Sons B (NYSE-WLYB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for John Wiley & Sons B (NYSE-WLYB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for John Wiley & Sons B (NYSE-WLYB) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ Fast Investor Answers

John Wiley & Sons B (NYSE-WLYB) Stock FAQ

Quick answers about John Wiley & Sons B (NYSE-WLYB) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$63.59
Estimated upside 26.5%
Valuation Rating
Undervalued
Estimated upside of 26.5%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Good
Current financial-health read

The current fair value estimate for John Wiley & Sons B (NYSE-WLYB) is $63.59. This implies an estimated upside of 26.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 26.5% versus the current market price.

An analyst price target for John Wiley & Sons B (NYSE-WLYB) is not currently available in the latest data file.

The current financial health read for John Wiley & Sons B (NYSE-WLYB) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for John Wiley & Sons B (NYSE-WLYB) is September 3, 2026.

Based on the current data, dividend yield is 2.9%, upcoming dividend amount is 1.43, ex-dividend date is July 7, 2026, payment date is July 23, 2026.

The current P/E ratio listed for John Wiley & Sons B (NYSE-WLYB) is 11.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for John Wiley & Sons B is 2.533 B.

The current enterprise value listed for John Wiley & Sons B is 3.233 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for John Wiley & Sons B is NYSE-WLYB, and the stock is listed on NYSE.

John Wiley & Sons B (NYSE-WLYB) is listed on NYSE.

The current debt-to-total-capital ratio listed for John Wiley & Sons B is 22.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for John Wiley & Sons B is 76.1%. Free float helps investors understand how much of the share base is available for public trading.